Results 131 to 140 of about 20,060 (180)
Some of the next articles are maybe not open access.
Early virologic response with pegylated interferons
Digestive and Liver Disease, 2004Recently, 12-week evaluation of viral response has been recommended as a means of reducing antiviral treatment morbidity and costs. The development of early stopping rules relies on an important assumption: rules must minimise discontinuation of treatment in patients who might ultimately respond after completion of the full course of therapy ...
openaire +2 more sources
Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C
Journal of Controlled Release, 2001Poly(ethyleneglycol) or PEG has proven to be of great value for a range of biomedical applications. A review the properties of PEG that lead to these applications is reported. Emphasis is placed on pharmaceutical uses of PEG--proteins, with specific discussion of the attributes of PEGylated alpha-interferon for treatment of hepatitis C.
A, Kozlowski, J M, Harris
openaire +2 more sources
Use of pegylated interferon in hypereosinophilic syndrome
Leukemia Research, 2012Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients.
Joseph H, Butterfield +1 more
openaire +2 more sources
Pegylated Interferon Monotherapy for Chronic Hepatitis C
Seminars in Liver Disease, 2004Interferon (IFN) alpha-2a has been attached to a branched 40-kD PEG molecule and IFN alpha-2b to a linear 12-kD PEG molecule leading to elimination half-lives of approximately 75 and approximately 30 hours, respectively. In one pivotal trial, 531 patients with chronic hepatitis C were assigned to receive either 180 microg of pegylated IFN alpha-2a once
Jenny, Heathcote, Stefan, Zeuzem
openaire +2 more sources
Pharmacokinetics of pegylated interferons: What is misleading?
Digestive and Liver Disease, 2004Available pegylated interferon (PEG-IFN) products confer enhanced therapeutic efficacy when compared with their IFN counterparts, and the added convenience of once-weekly dosing with no novel toxicities. PEG optimises the action of the IFNs by decreasing clearance rates, thereby allowing serum concentrations to remain constant over the dosing period ...
openaire +3 more sources
Hepatology, 2009
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
Vinod K, Rustgi +15 more
openaire +2 more sources
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
Vinod K, Rustgi +15 more
openaire +2 more sources
2005
Pegylated interfernon and ribavirin are recently used in treatment of chronic hepatitis C. Non.pegylated interferon and ribavirin were also used in same purpose. This meta -analysis is trieing to reveal which of these two combiations is more effective.
Štimac, Davor, Šimin, Marija
openaire +2 more sources
Pegylated interfernon and ribavirin are recently used in treatment of chronic hepatitis C. Non.pegylated interferon and ribavirin were also used in same purpose. This meta -analysis is trieing to reveal which of these two combiations is more effective.
Štimac, Davor, Šimin, Marija
openaire +2 more sources
Drugs, 2013
Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting.Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis.MEDLINE (
Nicolas, Flori +7 more
openaire +2 more sources
Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting.Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis.MEDLINE (
Nicolas, Flori +7 more
openaire +2 more sources
Reviews in gastroenterological disorders, 2002
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire +1 more source
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire +1 more source
Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta
International Immunopharmacology, 2018Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ).
Francesca, Gilli +3 more
openaire +2 more sources